Evaluate the Efficacy and Safety of FB704A in Adult With Severe Asthma

Summary

This is a randomized, placebo controlled and double blind study to evaluate the safety, tolerability, pharmacokinetics, and clinical activity of FB704A in adult patients with severe asthma. The study comprised a 4-week screening period, a 8-week treatment period and a 12-week follow-up period.

Timeline

Start

2021-09-30

Primary completion

2026-05-08

Completion

2026-05-08

Drugs

Indications